[Skip to Content]
[Skip to Content Landing]
Article
February 1972

Therapy of Histiocytosis X With Vincristine, Vinblastine, and Cyclophosphamide: The Southwest Cancer Chemotherapy Study Group

Author Affiliations

Houston; Charlottesville, Va; Galveston, Tex; St. Louis; Houston
From the departments of pediatrics, Baylor College of Medicine, Houston (Dr. Starling); University of Virginia, Charlottesville, Va (Dr. Donaldson); University of Texas Medical Branch, Galveston, Tex (Dr. Haggard); Washington University School of Medicine, St. Louis (Dr. Vietti); and University of Texas M.D. Anderson Hospital and Tumor Institute, Houston (Dr. Sutow). Dr. Donaldson is now with the Department of Pediatrics, University of Pennsylvania, and Oncology Training Program, Philadelphia Children's Hospital, Philadelphia.

Am J Dis Child. 1972;123(2):105-110. doi:10.1001/archpedi.1972.02110080083004
Abstract

We report the use of vincristine sulfate, vinblastine sulfate, and cyclophosphamide in the treatment of children with histiocytosis X. No children with solitary eosinophilic granulomas are included in this study. The complete remission rates for the three drugs were 50%, 20%, and 36%, respectively; and the complete remission plus partial remission rates are 50%, 55%, and 63%, respectively. Because of the small numbers of patients involved, and the design of the study, we could reach no conclusions regarding the relative efficacy of the drugs. We discuss factors influencing the response and present tabulated data regarding age, degree of involvement, duration of therapy, and result of therapy for each patient.

×